CYPHER Sirolimus-eluting Coronary Stent benefits from clinical success, worldwide grow...( New data from a Spanish study presented...),Health

New data from a Spanish study presented at the 2005 American Heart Association Scientific Sessions found that patients with bifurcation lesions fared significantly better when treated with the CYPHER Sirolimus-eluting Coronary Stent compared with the Taxus stent in the areas of late loss, re-treatment (total lesion revascularization or TLR) and re-blockage (restenosis). Bifurcated lesions are difficult to treat because the lesion is divided between two branches of the artery.

The 205-patient, randomized, comparative clinical trial found that at six months, patients with bifurcations in the CYPHER Stent arm were three times less likely to experience restenosis (9 percent for CYPHER Stent vs. 29 percent for Taxus stent, p=0.05) and undergo TLR (4 percent for CYPHER Stent vs. 13 percent for Taxus stent, p=0.05) than patients with bifurcations in the Taxus stent arm of the study. The late loss results in the main vessel and adjoining side branch also favored those patients treated with the CYPHER Stent.

This study was one of many clinical successes in 2005 for the CYPHER Stent. During the year, the CYPHER Stent experienced exponential growth worldwide, driven by numerous positive results from randomized controlled trials as well as meta-analyses of these trials presented at leading medical meetings and published in peer-reviewed journals including the New England Journal of Medicine (NEJM), Journal of the American Medical Association (JAMA), Circulation and the Journal of the American College of Cardiology (JACC). Clinical data results helped re-establish the CYPHER Stent as the leading drug-eluting stent globally.

"This year brought an impressive volume of positive new data on the CYPHER Stent," said Dennis Donohoe, MD, Worldwide Vice President, Clinical Research and Regulatory Affairs, Cordis Corporation. "Overwhelmingly, these data have confirmed the unsurpassed long-term efficacy and the trusted safety profile of the CYPHER
'"/>

Contact: Amy Meshulam
amy.meshulam@edelman.com
323-202-1065
Edelman Public Relations
21-Dec-2005

Page: 1 2 3
Related medicine news :

1. Four-year data suggest the CYPHER stent provides long-term efficacy and safety benefits
2. Study finds patients with chronic total occlusions benefit from the CYPHER Stent
3. New study results suggest better outcomes with the CYPHER Stent than brachytherapy
4. Sirolimus-eluting Coronary Stent outperforms paclitaxel eluting stent in seven study meta-analysis
5. Sirolimus-eluting Coronary Stent is cost effective vs. bypass surgery
6. Coronary surgery -- keeping the way clear
7. Coronary heart disease deaths in Ireland have halved in 15 years
8. Stenting of abdominal arteries offers welcome relief for intestinal angina
9. Stent-graft procedure improves outcomes of carotid aneurysm repair
10. Stents that release medication appear more effective than traditional stents
11. E/Tablet technology may provide benefits to patients, researchers